New Jersey Patent of the Month – July 2021

Your eye is a globe with fluid in it. As eye pressure fluctuates you might experience different eye conditions. Glaucoma is a condition where the optic nerve is damaged as a result of increased ocular pressure and can lead to vision loss. Aerie Pharmaceuticals, Inc. has developed a combination therapy that aims to control this eye pressure and prevent damage.

Their combination therapy uses an isoquinoline compound and a prostaglandin. These two compounds are covalently linked to form a salt. Testing the treatment on a patient with elevated eye pressure showed that, after 28 days of single doses, resulted in a significantly reduced eye pressure baseline. Aerie has put lots of research into developing solutions and treatments to tackle the root cause of eye pressure disorders. Most available treatments work to simply reduce the eye pressure, but Aerie intends to treat the condition that leads to reduced eye pressure. 

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts